These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1021 related articles for article (PubMed ID: 33162987)

  • 21. Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020.
    Yuan Y; Yu L; Jin Z; Wang Y; Gao M; Ding H; Zhuo X; Zhu X; Gao F; Zheng X; Ying G; Xu X; Kong Q; Lu S; Lv H
    Front Cell Infect Microbiol; 2021; 11():650487. PubMed ID: 33796489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of SARS-CoV-2 Neutralizing Antibodies to an Automated Chemiluminescent Serological Immunoassay.
    Grenache DG; Ye C; Bradfute SB
    J Appl Lab Med; 2021 Mar; 6(2):491-495. PubMed ID: 33098417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
    Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
    Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples.
    Manenti A; Maggetti M; Casa E; Martinuzzi D; Torelli A; Trombetta CM; Marchi S; Montomoli E
    J Med Virol; 2020 Oct; 92(10):2096-2104. PubMed ID: 32383254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Convalescent plasma - Is it useful for treating SARS Co-V2 infection?
    Ranganathan S; Iyer RN
    Indian J Med Microbiol; 2020; 38(3 & 4):252-260. PubMed ID: 33154232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of two commercial surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2.
    Müller K; Girl P; von Buttlar H; Dobler G; Wölfel R
    J Virol Methods; 2021 Jun; 292():114122. PubMed ID: 33705832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A rapid real-time polymerase chain reaction-based live virus microneutralization assay for detection of neutralizing antibodies against SARS-CoV-2 in blood/serum.
    Abidi SH; Imtiaz K; Kanji A; Qaiser S; Khan E; Iqbal K; Veldhoen M; Ghias K; Simas JP; Hasan Z
    PLoS One; 2021; 16(12):e0259551. PubMed ID: 34890401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.
    Dupont L; Snell LB; Graham C; Seow J; Merrick B; Lechmere T; Maguire TJA; Hallett SR; Pickering S; Charalampous T; Alcolea-Medina A; Huettner I; Jimenez-Guardeño JM; Acors S; Almeida N; Cox D; Dickenson RE; Galao RP; Kouphou N; Lista MJ; Ortega-Prieto AM; Wilson H; Winstone H; Fairhead C; Su JZ; Nebbia G; Batra R; Neil S; Shankar-Hari M; Edgeworth JD; Malim MH; Doores KJ
    Nat Microbiol; 2021 Nov; 6(11):1433-1442. PubMed ID: 34654917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.
    Kaku Y; Kuwata T; Zahid HM; Hashiguchi T; Noda T; Kuramoto N; Biswas S; Matsumoto K; Shimizu M; Kawanami Y; Shimura K; Onishi C; Muramoto Y; Suzuki T; Sasaki J; Nagasaki Y; Minami R; Motozono C; Toyoda M; Takahashi H; Kishi H; Fujii K; Tatsuke T; Ikeda T; Maeda Y; Ueno T; Koyanagi Y; Iwagoe H; Matsushita S
    Cell Rep; 2021 Jul; 36(2):109385. PubMed ID: 34237284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera.
    Ha B; Jadhao S; Hussaini L; Gibson T; Stephens K; Salazar L; Ciric C; Taylor M; Rouphael N; Edupuganti S; Rostad CA; Tompkins SM; Anderson EJ; Anderson LJ
    Microbiol Spectr; 2021 Oct; 9(2):e0045821. PubMed ID: 34494855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma.
    von Rhein C; Scholz T; Henss L; Kronstein-Wiedemann R; Schwarz T; Rodionov RN; Corman VM; Tonn T; Schnierle BS
    J Virol Methods; 2021 Feb; 288():114031. PubMed ID: 33275926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Establishment and clinical validation of an in-cell-ELISA-based assay for the rapid quantification of Rabies lyssavirus neutralizing antibodies.
    Schöler L; Le-Trilling VTK; Dittmer U; Fiedler M; Trilling M
    PLoS Negl Trop Dis; 2022 May; 16(5):e0010425. PubMed ID: 35536867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Convalescent plasma treatment of critically ill intensive care COVID-19 patients.
    Lindemann M; Lenz V; Knop D; Klump H; Alt M; Aufderhorst UW; Schipper L; Schwarzkopf S; Meller L; Steckel N; Koldehoff M; Heinold A; Heinemann FM; Fischer J; Hutschenreuter G; Knabbe C; Dolff S; Brenner T; Dittmer U; Witzke O; Herbstreit F; Horn PA; Krawczyk A
    Transfusion; 2021 May; 61(5):1394-1403. PubMed ID: 33784412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.
    Mazzini L; Martinuzzi D; Hyseni I; Benincasa L; Molesti E; Casa E; Lapini G; Piu P; Trombetta CM; Marchi S; Razzano I; Manenti A; Montomoli E
    J Immunol Methods; 2021 Feb; 489():112937. PubMed ID: 33253698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A flow cytometry-based assay to measure neutralizing antibodies against SARS-CoV-2 virus.
    Pscheidt VM; de Souza PO; Fazolo T; Modena JLP; Simeoni C; Teixeira D; Silva NB; Dos Santos KB; Júnior LR; Bonorino C
    Cytometry A; 2024 Jun; 105(6):446-457. PubMed ID: 38624015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection.
    Conzelmann C; Gilg A; Groß R; Schütz D; Preising N; Ständker L; Jahrsdörfer B; Schrezenmeier H; Sparrer KMJ; Stamminger T; Stenger S; Münch J; Müller JA
    Antiviral Res; 2020 Sep; 181():104882. PubMed ID: 32738255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantifying Neutralizing Antibodies in Patients with COVID-19 by a Two-Variable Generalized Additive Model.
    Liu KT; Gong YN; Huang CG; Huang PN; Yu KY; Lee HC; Lee SC; Chiang HJ; Kung YA; Lin YT; Hsiao MJ; Huang PW; Huang SY; Wu HT; Wu CC; Kuo RL; Chen KF; Hung CT; Oguntuyo KY; Stevens CS; Kowdle S; Chiu HP; Lee B; Chen GW; Shih SR
    mSphere; 2022 Feb; 7(1):e0088321. PubMed ID: 35107336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
    Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T
    J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.